Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/26/2022 | $18.00 | Outperform | Wedbush |
| 4/27/2022 | $6.00 | Neutral | Goldman |
| 12/17/2021 | $26.00 | Buy | HC Wainwright & Co. |
| 12/3/2021 | $38.00 | Outperform | Robert W. Baird |
| 12/3/2021 | $38.00 | Outperform | Baird |
| 12/2/2021 | $30.00 | Outperform | Oppenheimer |
| 10/19/2021 | $40.00 | Market Outperform | JMP Securities |
Wedbush initiated coverage of Vor Biopharma with a rating of Outperform and set a new price target of $18.00
Goldman initiated coverage of Vor Biopharma with a rating of Neutral and set a new price target of $6.00
HC Wainwright & Co. initiated coverage of Vor Biopharma with a rating of Buy and set a new price target of $26.00
SC 13D/A - Vor Biopharma Inc. (0001817229) (Subject)
SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)
SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with significant potential opportunities across oncology, gene therapy, and autoimmune disorders CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic wind
Strong progress across PureTech's portfolio, with significant near-term catalysts Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and $50 million buyback completed Strong balance sheet with expected operational runway for at least three years Company to host a webcast and conference call today at 9:00am EDT / 2:00pm BST PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces its half-yearly results for the six months ended June 30, 2024. The following information will be filed on Form 6-K w
Primary neutrophil engraftment of trem-cel achieved in all seven patients treated to dateAll three patients receiving multiple Mylotarg™ doses exhibited hematologic protection, further validating Vor Bio's approachConference call today, November 9 at 4:30 PM ET CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today presented updated clinical data from patients treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (VOR33) in patients with acute myeloid leukemia (AML). Guenther Koehne, MD, PhD, Deputy Director and Chief of Blood & Marrow Transplant and Hematologic Oncology
JMP Securities analyst Silvan Tuerkcan reiterates Vor Biopharma (NASDAQ:VOR) with a Market Outperform and maintains $12 price target.
Oppenheimer analyst Matthew Biegler reiterates Vor Biopharma (NASDAQ:VOR) with a Outperform and lowers the price target from $15 to $10.
Wedbush analyst David Nierengarten reiterates Vor Biopharma (NASDAQ:VOR) with a Outperform and maintains $11 price target.
4 - Vor Biopharma Inc. (0001817229) (Issuer)
4 - Vor Biopharma Inc. (0001817229) (Issuer)
4 - Vor Biopharma Inc. (0001817229) (Issuer)
8-K - Vor Biopharma Inc. (0001817229) (Filer)
8-K - Vor Biopharma Inc. (0001817229) (Filer)
8-K - Vor Biopharma Inc. (0001817229) (Filer)
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr. Choi will join the Vor Bio leadership team and will report directly to the company's President and Chief Executive Officer, Dr. Robert Ang. Dr. Choi brings to Vor Bio over twenty-five years of experience in public and private investment management, business development, and corporate strategy within the pharmaceutical and biotechnology industry. His deep expertise in structuring corporate partnerships and investments, managing complex transact
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint Medicines, bringing a wealth of industry experience and expertise to Vor Bio's Board. In his role at Blueprint Medicines, Dr. Namouni has demonstrated exceptional leadership in building the company's fully integrated business and advancing a broad pipeline of innovative medicines to address significant medical needs in oncology/hematology and allergy/inflammation. With over two decades of experience in
CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that Eyal C. Attar, M.D., has joined Vor Bio as Chief Medical Officer (CMO). Dr. Attar brings more than 20 years of demonstrated clinical experience to the position, with previous roles as a clinician, bench researcher and clinical developer of treatments for hematologic malignancies. "This is a time of tremendous momentum for Vor Bio with initial data expected later this year for our ongoing clinical trial of VOR33, and as we work towards our IND submission for VCAR33ALLO in the first half of next year," said Dr. Robert Ang, Vor Bio's President a
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr. Choi will join the Vor Bio leadership team and will report directly to the company's President and Chief Executive Officer, Dr. Robert Ang. Dr. Choi brings to Vor Bio over twenty-five years of experience in public and private investment management, business development, and corporate strategy within the pharmaceutical and biotechnology industry. His deep expertise in structuring corporate partnerships and investments, managing complex transact
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefit VCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with significant potential opportunities across oncology, gene therapy, and autoimmune disorders PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity, Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with significant potential opportunities across oncology, gene therapy, and autoimmune disorders CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic wind